Opportunities
Search

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-05

Buyer: Vilniaus miesto savivaldybės administracija | Notice type: cn-standard | Procedure: restricted | Contract: works | Deadline: 2027-02-05

Buyer: Vilniaus miesto savivaldybės administracija | Notice type: cn-standard | Procedure: restricted | Contract: works | Deadline: 2027-02-05

The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.

Buyer: Louth and Meath Education and Training Board 1384 | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-08

Buyer: AB "Lietuvos geležinkeliai" | Notice type: cn-social | Procedure: restricted | Contract: services | Deadline: 2027-02-08

Buyer: УНИВЕРСИТЕТСКА МНОГОПРОФИЛНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ "СВ. ИВАН РИЛСКИ" ЕАД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-02-08

Buyer: УНИВЕРСИТЕТСКА МНОГОПРОФИЛНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ "СВ. ИВАН РИЛСКИ" ЕАД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-02-08

This Notice of Funding Opportunity (NOFO) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK. The purpose of this Centers program is to bring together basic and clinical investigators to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases within the NIDDK's mission. DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner. Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of the NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding.

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-02-10

The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie: 1. Phenotypes associated with addictive behaviors and/or vulnerability to distinct stages along the substance use disorders (SUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery); 2. Behaviors associated with SUD (e.g. impulsivity, novelty seeking, delayed discounting, and other genetically-associated phenotypes); and 3. Comorbidities that demonstrate genetic correlations with phenotypes and behaviors linked with SUD (e.g. anxiety, stress, poor maternal care, social defeat, and other paradigms). Applications may examine any type of genomic variant, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, and/or data-based approaches that integrate multi-level omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. Other areas of interest include genomics analysis at the circuit level and the application of neuroscience to genomics studies. NIDA expects these studies to uncover novel mechanisms that contribute to various stages across the SUD trajectory and inform future studies about potential targets and therapeutic strategies for addiction.